Hépatite aiguë médicamenteuse à l’anakinra chez une patiente traitée pour une maladie de Still de l’adulte

Abstract: Introduction: Adult-onset Still''s disease is characterized by non-specific polymorphic features. The efficacy of anakinra, an IL-1 receptor antagonist, has been shown in several studies. This medication is well-tolerated, and only one case of severe hepatitis has been previously reported. Case report: A 22-year-old woman presented with fever, rash, arthritis, and pericarditis, associated with systemic inflammatory response syndrome and elevated ferritin serum level with low glycosylated ferritin. Adult-onset Still''s disease was diagnosed, but treatment with steroids did not achieve remission. The patient was then treated with anakinra, which resulted in spectacular improvement, but 3 weeks after the initiation of the treatment she experienced severe hepatitis that resolved after the discontinuation of anakinra. Conclusion: Hepatitis is a rare side effect of anakinra and the monitoring of liver tests should be recommended during anakinra therapy. [Copyright &y& Elsevier]